NDANASALSPRAY, METERED
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
GIMOTI (metoclopramide hydrochloride) by Pfizer is gastric, biliary, or pancreatic secretions. First approved in 2020.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GIMOTI is a nasal spray formulation of metoclopramide hydrochloride, a prokinetic agent approved by FDA in June 2020. It treats gastroesophageal reflux disease and acute/recurrent diabetic gastroparesis by enhancing gastric contractions and accelerating gastric emptying through acetylcholine sensitization. The nasal route provides an alternative delivery mechanism to traditional oral formulations.
$0.003BPart D
Peak12.4 years to LOEProduct is in peak commercial phase with modest Part D utilization, suggesting a niche positioning within the prokinetic market with a smaller commercial footprint.
Mechanism of Action
gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GIMOTI offers limited direct job openings (0 linked roles reported) due to its niche market position and modest commercial footprint; however, roles do exist in brand management, field sales, and market access within Pfizer's broader GI portfolio. Career growth depends on expanding adoption or supporting transition strategy ahead of 2029–2030 LOE.
Worked on GIMOTI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.